Lipoatrophy associated with rapid-acting insulin analogues in young patients with type 1 diabetes mellitus

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 14, Issue 2, 2008, Pages 117-118

  Szypowska, Agnieszka ^a   Skórka, Agata ^b   Pańkowska, Ewa ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NONE

Author keywords

Aspart; Children; Complications; Lispro

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN LISPRO; ISOPHANE INSULIN; MIXTARD 30; MIXTARD 50;

ABDOMEN; ADULT; ARTICLE; BUTTOCK; CASE REPORT; CATHETER; CHILD; CONTINUOUS INFUSION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; EVENING DOSAGE; FEMALE; HUMAN; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LIPOATROPHY; MALE;

EID: 84904845046     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Ampudia-Blasco F.J., Girbes J., Carmena R.: A case of lipoatrophy with insulin glargine (Letter). Diabetes Care, 2005, 28, 2983.
2. Griffin M.E., Feder A., Tamborlane W.V.: Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? (Letter). Diabetes Care, 2001, 24,174.
3. Ramos A.J., Farias M.A.: Human insulin-induced lipoatrophy. A successful treatment with glucocorticoid. Diabetes Care, 2006, 29, 926-927.
4. Reeves W.G., Allen B.R., Tattersall R.B.: Insulin induced lipoatrophy evidence for an immune pathogenesis. BMJ, 1980, 1, 1500-1506.
5. Atlan-Gepner C., Bongrand P., Farnarier C. i wsp.: Insulin-induced lipoatrophy in type 1 diabetes: a possible tumor necrosis factor-alpha-mediated dedifferentiation of adipocytes. Diabetes Care, 1996, 19, 1283-1285.
6. Lindholm A., Jensen L.B., Home P.D. i wsp.: Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care, 2002, 25, 876-882.
7. Fineberg N.S., Fineberg S.G., Anderson J.H. i wsp.: Immunologic effects of insulin lispro [Lys (B28), Pro (B29 human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes, 1996, 45, 1750-1754
8. Richardson T., Kerr D.: Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am. J. Clin. Dermatol., 2003, 4, 661-667.
9. Zinman B.: Insulin pump therapy and rapid acting insulin: what have we learned? Int. J. Clin. Pract., 2001, 123, 47-50.
10. Chantelau E., Reuter M., Schotes S., Starke A.A.: Severe lipoatrophy with human insulin: successfully treated by CSII (Letter). Diabet. Med., 1993, 10, 580-581.